Stability for 6 months and accuracy of a specific enteral caffeine base preparation for a multisite clinical trial

Br J Clin Pharmacol. 2023 Aug;89(8):2631-2635. doi: 10.1111/bcp.15739. Epub 2023 Apr 21.

Abstract

The 'Intermittent Hypoxia and Caffeine in Infants Born Preterm (ICAF)' study (NCT03321734) uses an extemporaneously compounded enteral caffeine base solution for its study drug. The primary aim of this report is to determine the stability of this specific enteral caffeine base preparation stored for up to 6 months and assess optimal storage temperature. To analyse stability, caffeine solutions were prepared and stored at 4°C and 25°C (room temperature). The caffeine concentrations were analysed over time using high-performance liquid chromatography (HPLC). To confirm the accuracy of compounded caffeine concentrations, study drug samples from three research pharmacies were analysed. Stability results showed that caffeine concentrations are within 5% of the expected concentration when stored for up to 6 months at room temperature. Our results also show that accurate caffeine concentrations were achieved by multiple research pharmacies.

Keywords: HPLC; clinical pharmacology; drug analysis; drug information; neonatology; paediatrics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Caffeine*
  • Chromatography, High Pressure Liquid
  • Drug Compounding
  • Drug Stability
  • Drug Storage
  • Humans
  • Infant, Newborn

Substances

  • Caffeine

Associated data

  • ClinicalTrials.gov/NCT03321734